The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Cited by (614)

Items 501–600 of 614

1. A literature mining method to judge whether there are uncertainties in empirical-dependent antineoplastic drug distribution in specific clinical scenarios
   Xiaoyang Ji, Zhendong Feng, Qiangzu Zhang, Zhonghai Zhang, Yanhui Fan, Renhua Na, Gang Niu · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
2. Using Chemical Biology to Modulate Antibody Activity
   Jittasak Khowsathit · 2019 · KU ScholarWorks (The University of Kansas)
3. Immune checkpoint inhibitors for the treatment of glioblastoma: Where we are
   Bryan Lu, Senxi Du, Xiao–Tang Kong · 2020 · Journal of Solid Tumors
4. The role of Programmed Death-Ligand 1 expression in nasopharyngeal carcinoma
   Nadya Dwi Karsa · 2021 · Oto Rhino Laryngologica Indonesiana
5. Peer Review #2 of "Gender-related disparities in the frequencies of PD-1 and PD-L1 positive peripheral blood T and B lymphocytes in patients with alcohol-related liver disease: a single center pilot study (v0.1)"
   2021 · PeerJ
6. Estudio de las interacciones de PD-1H y sus ligandos en la respuesta inmunitaria murina = The study of the interactions between PD-1H and their putative ligands in the murine immune response
   Irene del Vigo Soto · 2021
7. Prediction of patients’ response to immune checkpoint inhibitors in the treatment of advanced NSCLC
   Mustafa Abdo · 2021
8. ALDH2 Polymorphism rs671 is A Predictor of Immune Checkpoint Inhibitor Efficacy Against Chest Malignancies
   Akiko Matsumoto, Chiho Nakashima, Shinya H Kimura, Eizaburo Sueoka, Naoko Sueoka‐Aragane · 2021 · Research Square
9. Naviko imuninės mikroaplinkos įtaka sergant nesmulkiųjų ląstelių plaučių vėžiu
   Giedrė Gurevičienė, Brigita Šitkauskienė, Marius Žemaitis · 2020 · Pulmonology and allergology
10. A theoretical model for an electromagnetic antenna in induction of virtual T cells
    Massimo Fioranelli, Alireza Sepehri, Maria Grazia Roccia, Aroonkumar Beesham, Dana Flavin · 2021 · Network Modeling Analysis in Health Informatics and Bioinformatics
11. Potensi Chimeric Antigen Receptor T Cell (CAR-T Cell) dengan Target Prostate-Specific Membrane Antigen (PSMA) Termodifikasi CRISPR/Cas9 sebagai Terapi Kanker Prostat
    Ali Habibi, Siti Zulaikha Risqiyani, Dwi Ari Santi Putri · 2021 · JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia
12. Análise de mediadores solúveis de promoção e supressão da resposta imune em pacientes com a síndrome de deleção 22q11.2
    Diogo Cordeiro de Queiroz Soares · 2020
13. Expressão de PD1, PD-L1, PD-L2 e CD8+ em carcinomas escamocelulares cutâneos de alto risco em cabeça e pescoço
    Gustavo Nunes Bento · 2021
14. La Vía de PD-1/PD-L1 como blanco de inmunoterapia contra el Cáncer
    Angélica Arce Araya, Carolina Hernández García, Paula Neily Younes, Valeria Mata Jinesta, María Belén Serrano Silva, Carolina Ulate Sancho, Ledis Reyes Moreno · 2021 · Revista Médica de la Universidad de Costa Rica
15. Параметры микроокружения опухоли определяют эффективность анти-PD-1/PD-L1-терапии
    Л. А. Таширева, Dariya T. Muravyova, Natalya O. Popova, Viktor E. Goldberg, Sergey Vladimirovich Vtorushin, Перельмутер Владимир Михайлович · 2021 · Biochemistry (Moscow)
16. Driving Mechanisms of Different Tissues Cellular Cycles in Normand in Cancer Pathology from the Point of View of Thermodynamics,Biophysics and Biochemistry
    Michail R. Ponizovskiy · 2021 · Journal of Cancer Research Reviews & Reports
17. Regulation of Immune Responses
    Arash Maleki, Ambika Manhapra, Hazem M. Mousa, Charles Stephen Foster · 2021 · Springer eBooks
18. Dual Immunotherapy in a Patient with Rapidly Progressive Metastatic Melanoma Without Failure of Grafted Kidney
    Charles Junior Limula, Abigail L Gee, Jonathan Potts, Hannah Taylor, Christopher E. Herbert, Helen R. Winter · 2022 · EMJ Oncology
19. A review of neurological complications of immune-checkpoint inhibitors
    Domantas Valančius, I. Zagorskienė, Aušra Klimašauskienė · 2021 · Neurologijos seminarai
20. Regulation of Immune Responses
    Arash Maleki, Ambika Manhapra, Hazem M. Mousa, Charles Stephen Foster · 2022 · Springer eBooks
21. The Differences of Programmed Death Ligand 1 Expression Between the Early Stages and Advanced Stages of Nasopharyngeal Carcinoma in DR. M Djamil Padang Hospital
    Nadya Dwi Karsa, Sukri Rahman, Al Hafiz, Hirowati Ali, Hafni Bachtiar · 2021 · Advances in health sciences research/Advances in Health Sciences Research
22. Peer Review #1 of "Gender-related disparities in the frequencies of PD-1 and PD-L1 positive peripheral blood T and B lymphocytes in patients with alcohol-related liver disease: a single center pilot study (v0.1)"
    2021 · PeerJ
23. A Transcriptomic Meta-Analysis Identifies Differentially Expressed Genes across Different Types of Cancer and Their Association with Checkpoint Inhibitor Immunotherapy
    Ahmed Al-Khudhair, Pervaiz Dar, Shahnawaz Imam, Sadik Khuder, Juan Carlos Jaume · 2019
24. Caracterização do perfil das células T foliculares do centro germinativo e circulantes
    Giovana Alonso · 2020
25. The journey of dostarlimab: a successful weapon for cancer treatment
    Rouchan Ali, Sharma Arvind Virendra, Pooja A. Chawla · 2022 · Exploration of Medicine
26. Advances in PD-1 Expression Levels and Organismal Immunity in Pulmonary Infectious Diseases
    龙志 张 · 2023 · Advances in Clinical Medicine
27. Which technology performs better? From sample volume to extraction and molecular profiling
    Ettore Capoluongo, Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone · 2023 · Elsevier eBooks
28. Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies
    Breanna P Caruso, Amy E. Moran · 2023 · Trends in cancer
29. CLINICOPATHOLOGICAL CHARACTERISTICS OF INVASIVE BREAST CARCINOMA ON PDL-1 IMMUNOHISTOCHEMICAL EXPRESSION IN H. ADAM MALIK HOSPITAL MEDAN
    Daniel KristianPrawira Lesmana, Denny Rifsal Siregar, Dedy Hermansyah · 2023 · Sumatera Medical Journal
30. PERAN INTERLEUKIN-6 SELAMA INFEKSI VIRUS
    Universitas Methodist Indonesia, Sumihar M. R. Pasaribu · 2022 · Majalah Ilmiah METHODA
31. Editorial: Immunometabolism and therapeutic targeting of aggressive cancers
    Maša Ždralević, Jacques Pouysségur · 2023 · Frontiers in Oncology
32. Expression of Recombinant Human Programmed Cell Death Protein-1 and Development of Camel Polyclonal Antibody
    Mohammad Hosseininejad-Chafi, Zahra Kianmehr, Kamran Pooshang Bagheri, Fatemeh Kazemi‐Lomedasht, Mahdi Behdani · 2022 · Internal medicine today
33. IMMUNOHISTOCHEMICAL EXPRESSION OF PROGRAMMED DEATH-LIGAND 1 (PDL-1) IN COLORECTAL ADENOCARCINOMA AT H. ADAM MALIK GENERAL HOSPITAL MEDAN
    Ramadansyah, Tengku Ibnu Alferraly, Jessy Chrestella, Delyuzar, Lidya Imelda Laksmi · 2023 · International Journal of Research Publications
34. Correlation between stromal Th and Tc lymphocytes and PD-L1 expression in early breast cancer tumors
    Jelena Vučinić, Ljiljana Vučković, Janja Raonić · 2023 · Folia Histochemica et Cytobiologica
35. Introductory Chapter: Navigating Autoimmunity – From Molecular Mechanisms to Therapeutic Horizons
    Mourad Aribi · 2024 · IntechOpen eBooks
36. Additional file 7 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu, Ruoxu Chen, Xudong Zhang, Ruiting Fu, Lin Tao, Wei Ping Jia · 2022 · Figshare
37. Additional file 3 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu, Ruoxu Chen, Xudong Zhang, Ruiting Fu, Lin Tao, Wei Ping Jia · 2022 · Figshare
38. Additional file 5 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu, Ruoxu Chen, Xudong Zhang, Ruiting Fu, Tao, Lin, Wei Ping Jia · 2022 · Figshare
39. Additional file 4 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu, Ruoxu Chen, Xudong Zhang, Ruiting Fu, Tao, Lin, Wei Ping Jia · 2022 · Figshare
40. Additional file 6 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu, Ruoxu Chen, Xudong Zhang, Ruiting Fu, Lin Tao, Wei Ping Jia · 2022 · Figshare
41. The Key Resolver of Immune Tolerance: The Role of the PD-1/PD-L1 Signaling Pathway in Physiological and Pathological Pregnancy
    Remziye Kendirci, Ertan Katırcı, Leyla Satı · 2024 · TURKISH JOURNAL OF HEALTH AND SPORT (TJHS)
42. Characterization of Natural Killer cells infiltrating irradiated murine tumors through flow cytometry
    Jérémy Baude, Riad Ladjohounlou, Emeric Limagne, Lisa Froidurot, Véronique Morgand, Céline Mirjolet · 2024 · Methods in cell biology
43. Development of an immunogenic cell death-related lncRNAs signature for prognostic risk assessment in gastric cancer
    Wen Li, Fan Ding, Jie Zhang · 2024 · Translational Cancer Research
44. Immunotherapy and Immunotherapeutic Drugs
    Hasan Akkoç · 2024
45. Comparison of the PD-1 expression level in peripheral blood of Multiple Sclerosis and Neuromyelitis Optica patients
    Tayebe Aghaie, Melika Gorgani, Morteza Motallebnezhad, Mir Hadi Jazayeri · 2024 · Alborz University Medical Journal
46. PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs
    Katarzyna Dziubek, Jakub Faktor, Kiran Bharat Lokhande, Ashish Shrivastava, Ines Papak, Elżbieta Chruściel, Magdalena Pilch, Theodore Hupp, Natalia Maria Marek-Trzonkowska, Ashutosh Singh et al. · 2024 · Cell Communication and Signaling
47. Antigens
    Marie C. Béné, Anna Porwit‐MacDonald · 2025 · Cambridge University Press eBooks
48. PD-1 involvement in CD8+ tumor-infiltrating lymphocytes in patients with colonic-derived peritoneal adenocarcinoma
    Huihui Hu, Man Zhang · 2025 · Brazilian Journal of Medical and Biological Research
49. Disulfidptosis ‒ related lncRNAs are biomarkers of prognosis and immune response in Head and Neck Squamous Cell Carcinoma
    Ruilin Wang, Qi Zhang, Yulin Ma, Xuelin Liu, Tian Lan, Hongling Li · 2025 · Brazilian Journal of Otorhinolaryngology
50. Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
    Rishi Kant, Prashanjit Roy, Amandeep Kaur, Ranjeet Kumar · 2025 · Journal of Coloproctology
51. The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery
    Xiuping Zhang, Maodong Fu, Zhiyong Li, Feng Shen, Huan Chen, Zhiming Wang, Jingmei Zheng · 2025 · Future Science OA
52. Neue Immuncheckpointinhibitoren und Kombinationen
    Umut-Ulas Yesilyurt, Thomas Hilser, N. Klümper, Mulham Al‐Nader, Aykhan Isgandarov, Milan Wahl, Christopher Darr, Viktor Grünwald · 2025 · Die Onkologie
53. Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials
    Ana Paula Bedin, Gabriela N Maffezoli, Luis Henrique Rios Moreira Rego, Maria Isadora Rodrigues Carlos, Pedro Henrique Albuquerque da Silva, Francisco Cézar Aquino de Moraes · 2025 · Clinical & Translational Oncology
54. Effects of proinflammatory cytokines and programmed cell death on cognitive domains in older age patients with bipolar disorder
    Pei-Ying Lee, Chih Chiang Chiu, Po‐Hsiu Kuo, Cho‐Yin Huang, Shang‐Ying Tsai, Chian‐Jue Kuo, Wen-Yin Chen · 2025 · Annals of General Psychiatry
55. High PD-L2 Expression Is Associated with Better Disease-Free Survival in Patients with Intrahepatic Cholangiocarcinoma
    Shule Chen, Jie Meng, Lei Liu, Peilu Huang, Zhichao Xie, Zhiguo Zhang, Sansheng Ma, Yichuang Huang, Chunhua Bei, Lingyun Liu · 2025 · Cancer Management and Research
56. Progress in undestanding of relationship between P2X7R and pancreatic ductal adenocarcinoma
    Zhao-Chun Chi · 2025 · World Chinese Journal of Digestology
57. Association of immune cells with the risk of basal cell carcinoma: A bidirectional Mendelian randomized study
    Suyao Wang, Yuying Li, Shaolei Huang · 2025 · Medicine
58. Programmed cell death ligands 1 and 2 and their receptor programmed cell death 1: Expression, regulation, and function at the maternal-conceptus interface in pigs
    Inkyu Yoo, Yugyeong Cheon, Eunhyeok Choi, Seonghyun Kim, Tae Sub Park, Hakhyun Ka · 2025 · Animal Reproduction Science
59. Role of genetic polymorphisms within different genes and associated risks of cancer development (Review)
    Runjhun Mathur, Noopur Khare, Gaurav Saini, Sheo Prasad Shukla, Abhimanyu Kumar Jha · 2025 · World Academy of Sciences Journal
60. An overview of small molecule approaches in cancer immunotherapy
    John D. Chisholm, William Garrow Kerr · 2025 · Elsevier eBooks
61. Interaction between HBsAg response and the prognosis of patients with HBV-associated HCC receiving anti-PD-1/PD-L1
    Xia Zhang, Qing Xu, Qin-Xia Ma, Yonglin Yang · 2025 · BMC Infectious Diseases
62. Additional file 1 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
63. Additional file 6 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
64. Additional file 8 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
65. Additional file 7 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
66. Additional file 4 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
67. Additional file 1 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Liu, Ping, Ruoxu Chen, Zhang, Xudong, Ruiting Fu, Tao, Lin, Jia, Wei · 2022 · Figshare
68. Additional file 1 of Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
    Zhang, Hao, Dai, Ziyu, Wu, Wantao, Wang, Zeyu, Zhang, Nan, Zhang, Liyang, Zeng, Wen-Jing, Liu, Zhixiong, Cheng, Quan · 2021 · Figshare
69. Additional file 3 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
70. Additional file 5 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
71. Additional file 1 of ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies
    Matsumoto, Akiko, Chiho Nakashima, Kimura, Shinya, Eizaburo Sueoka, Aragane, Naoko · 2021 · Figshare
72. Additional file 2 of Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
    Xingyu Li, Zhang, Yanyan, Zhu, Cheng, Xu, Wentao, Xiaolei Hu, Martínez, Domingo Antonio Sánchez, Romero, José Luis Alonso, Yan, Ming, Dai, Ying, Wang, Hua · 2024 · Figshare
73. Additional file 2 of Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Liu, Ping, Ruoxu Chen, Zhang, Xudong, Ruiting Fu, Tao, Lin, Jia, Wei · 2022 · Figshare
74. Alternative signaling pathways for regulation of programmed cell death 1 protein expression in T lymphocytes
    E. V. Batorov, P. V. Vasilchenko, E. R. Chernykh · 2025 · Advances in molecular oncology
75. Cell-Permeable Morpholino Inhibits Programmed Death-Ligand 1 at mRNA Level and Potentiates Antitumor Immunity in Breast Cancer
    Sudipta Sarkar, Ujjwal Ghosh, Subhamoy Pratihar, Surajit Sinha · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
76. Comparison of Inflammatory Cytokine Responses in DENV-1 Monoinfection Versus Coinfection with DENV-4
    Monalisa Mohanty, Archana Tripathy, Prabhudutta Mamidi, Sailendra Panda, Amrita Ray, Sanjeev Kumar Bhoi, Anupam Dey, Gaurav Chhabra, Diksha Mohapatra, Madhab Charan Mandal et al. · 2026 · Vector-Borne and Zoonotic Diseases
77. Overview of vaccine strategies against epidermal growth factor receptor in brain tumors
    Adel Azghadi, Arpan R. Chakraborty, John Howard Sampson, Michael D. Staudt · 2026 · Elsevier eBooks
78. Mixed Lymphocyte Reaction: Functional Immune Profiling in Transplantation and Beyond
    Nurtilek Galimov, Aruzhan Asanova, Sholpan Altynova, Aidos K. Bolatov · 2026 · Diagnostics
79. The role of immune checkpoint proteins PD1 and PD-L1 during cancer resistance
    Vidya Balasubramanian, Sivasankaran Munusamy Ponnan, Sridhar Muthusami, Vijayakumar Velu · 2026 · Elsevier eBooks
80. Effets de l’hypoxie sur la régulation de l’expression et la fonction de la tétraspanine CD9 dans les leucémies aiguës lymphoblastiques de l’enfant
    Jérémie Rouger · 2018
81. Etude et origine des neutrophiles régulateurs dans l'infection pulmonaire
    Florent Creusat · 2019 · theses.fr (ABES)
82. Effet de l'inhibition par ARN interférence de la thrombospondine-1 sur la potentialisation de la réponse immune dans un contexte tumoral
    Elie Marcheteau · 2019
83. Les lymphocytes T folliculaires auxiliaires dans la sclérodermie systémique
    Laure Ricard · 2019
84. Identification de nouvelles pistes de ciblage thérapeutique dans le lymphome folliculaire
    Cédric Rossi · 2018
85. Rôle de TRIM33 dans l'immunothérapie anti-tumorale radio-induite
    Anaïs Assouvie · 2021 · theses.fr (ABES)
86. An orthotopic syngeneic mouse model to study the role of DCIR in colorectal cancer
    Giulia Trimaglio · 2020 · theses.fr (ABES)
87. Optimisation des vaccins peptidiques anti-cancers à but thérapeutique par l'utilisation d'un vecteur omposé de nanotubes de nitrure de bore et combinaisons avec les anticorps anti-PD-L
    Laurie Rangan · 2020
88. Combined nanoparticle-mediated photothermal therapy to enhance CAR-T cell immunotherapy efficacy in stiff cholangiocarcinoma
    Sonia Becharef · 2024
89. Immune Checkpoint Molecules: Structure, Function, and Expression
    Lobat Tayebi, Mohsen Abdolmaleki · 2026 · Springer eBooks
90. Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies
    Yayu Chen, Zhiye Ye, Yanping Wang, Shanlan Liang, Daniel Xin Zhang · 2026 · Cancer Drug Resistance
91. Bridging B-cell autoimmunity and oncology: the PD-1/PD-L1 paradox in systemic lupus erythematosus
    Yunfeng Guan, C Chen, Yulong Hou · 2026 · Frontiers in Immunology
92. Comparative efficacy of Chinese-developed versus imported PD-1/PD-L1 inhibitors in first-line combination therapy for advanced NSCLC: a systematic review and network meta-analysis
    Jingting Yang, Rui Min, Hongcheng Zhong, Chihua Li, Yuanjia Hu · 2026 · Journal of the National Cancer Center
93. Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor)
    Chang Qin, Chuan Yang, Yuqi Wang, Ye Zou, Xiaojie Ding · 2026 · Frontiers in Immunology
94. Feasibility of Minimally Invasive Surgery After Chemo-Immunotherapy in Locally Advanced and Oligometastatic NSCLC: Technical Aspects and Surgical Outcomes
    Giorgio Cannone, Luigi Lione, Viola Sambataro, Alessandro Bonis, Vincenzo Verzeletti, Alessandro Rebusso, Giovanni Maria Comacchio, Eleonora Faccioli, Giulia Pasello, Laura Bonanno et al. · 2026 · Cancers
95. Exploring New Therapeutic Targets in NSCLC: Unraveling the Interplay Between NTRK and PD-L1 Expression
    Jair Manuel Gutierrez Herrera, M. Angeles Montero-Fernandez, Georgia Kokaraki, Luigi De Petris, Raul Maia Falcão, Ricardo Guijarro, Simon Ekman, Cristian Ortiz‐Villalón · 2026 · Journal of Respiration
96. Breaking and Making Tolerance: The PD-1/PD-L1 Axis in Lupus Nephritis
    Yachao Li, Xinyi Fang, Xiang Gao, Chi Liu · 2026 · Immunological Investigations
97. Optimizing immunotherapy–radiotherapy synergy in triple-negative breast cancer: mechanisms, clinical evidence, and therapeutic windows
    Lu Wang, Xin Bai, Fan Wang, Chenming Du, Jianming Tang · 2026 · Frontiers in Immunology
98. Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity
    Jianwei Xu, Pan Yang, Xixiang Yang, Yaoyao Shu, Lirong Zhang, Jiayi Zhou, Ling Li, Yichang Ren, Zichao Yang, Yibei Xiao et al. · 2026 · Journal of Medicinal Chemistry
99. Targeting immunosuppressive tumor microenvironment to combat immunotherapy resistance: From mechanistic insights to therapeutic strategies
    Pengfei Su, Yingjing Zhang, Tian Yu, 王元宇, 牟一平, Weiwei Jin · 2026 · International Immunopharmacology
100. Programmed cell death ligand 2 (PD-L2) expression is inversely correlated with human papillomavirus status in oropharyngeal squamous cell carcinoma (OPSCC) tumors
     Jeff J. Johnson, Wanrui Wang, Zonggao Shi, Annie Roble, Brian Crowley, Madison McFarland, Jing Yang, Daniel L. Miller, Mark William Lingen, Mary Sharon Stack · 2026 · Oral Oncology Reports